The Experts below are selected from a list of 156 Experts worldwide ranked by ideXlab platform
Karel Indrak - One of the best experts on this subject based on the ideXlab platform.
-
Importance of determination of serum Beta-2-Microglobulin levels in patients with Hodgkin's lymphoma
Vnitr̆ní lékar̆ství, 2002Co-Authors: Raida L, Tomas Papajik, Antonin Hlusi, Edgar Faber, Renata Urbanova, Heczko M, Jancíková M, Jana Zapletalova, Komenda S, Karel IndrakAbstract:The authors evaluated retrospectively in a group of 69 adult patients with Hodgkin's lymphoma the relationship between the Beta-2-Microglobulin serum level, basic demographic parameters (age, sex) and factors characterizing the extent (stage III and IV, "bulk" or mediastinal mass, number of affected areas of lymph nodes) and activity of the tumour (presence of B-symptoms, red cell sedimentation rate, haemoglobin, albumin and lactate dehydrogenase level, number of leucocytes and lymphocytes). They analyzed also the possible prognostic impact of Beta-2-Microglobulin on the therapeutic response risk of relapse and patient's survival. Methods of univariant statistical analysis confirmed the correlation of Beta-2-Microglobulin level with all investigated metric parameters of patients (advanced age, number of affected nodes, red cell sedimentation rate and lactate dehydrogenase level, lower albumin, haemoglobin level, numbers of leucocytes and lymphocytes). In multivariant analysis however the only independent metric markers significantly associated with an elevated protein level were more advanced age of the patients (P = 0.0002) and a lower number of leucocytes (P = 0.05). The values of Beta-2-Microglobulin was not influenced by the extent of the tumour (stage III and IV, "bulk" or mediastinal mass, higher number of affected areas of lymph nodes). Significantly more frequently elevated protein values were recorded in patients with manifestations of B symptoms associated with the diagnosis (P = 0.0003). Multivariant analysis did not prove the importance of the serum level of Beta-2-Microglobulin as a prognostic factor in the sense of predicted remission, development of a relapse or death in conjunction with progression of Hodgkin's lymphoma.
-
Clinical significance of correction of serum beta 2-Microglobulin levels for serum creatinine in multiple myeloma.
Acta Universitatis Palackianae Olomucensis Facultatis Medicae, 1991Co-Authors: Scudla, Vavrdová, Budíková M, Karel IndrakAbstract:In the group of 78 patients with multiple myeloma a comparison of the clinical significance of measured and corrected serum beta 2-Microglobulin levels was carried out. There was confirmed a significant relationship between serum beta 2-Microglobulin and serum creatinine levels. Pretreatment and follow-up of uncorrected serum beta 2-Microglobulin levels were useful in confirming tumor mass grade (assessed according to Durie and Salmon or the British Medical Research Council) and survival prediction. No gain was evident from correcting the serum beta 2-Microglobulin for the level of serum creatinine (according to Cassuto et al or Garewal et al).
Ondrasík M - One of the best experts on this subject based on the ideXlab platform.
-
Beta-2-Microglobulin and ankylosing spondylitis
Casopís lékar̆ů c̆eských, 1990Co-Authors: Mateicka F, Cebecauer L, Bosák, Bosmanský K, Ondrasík MAbstract:Serum Beta-2-Microglobulin was examined by radioimmunoassay in 103 patients with ankylosing spondylitis and 111 healthy blood-donors. Statistically significant difference between the group of patients and healthy individuals was found related to increased levels of this protein in patients with ankylosing spondylitis. Furthers correlation analysis of Beta-2-Microglobulin in patients with ankylosing spondylitis and chosen clinical and humoral parameters of the disease activity was performed. Positive, statistically significant correlation with erythrocyte sedimentation rate, plasmatic gamma globulins, duration of morning stiffness and global activity of the disease was proved. Higher levels of Beta-2-Microglobulin in patients with ankylosing spondylitis could be attributed to activation of monocyte macrophages system in subpopulation of cytotoxic T-lymphocytes, which might be the evidence of the involvement of cytotoxic-T cell mechanisms in the pathogenesis of this disease.
G. A. Müller - One of the best experts on this subject based on the ideXlab platform.
-
Do different dialysis-membranes affect beta 2-Microglobulin kinetics during chronic hemodialysis?
International Journal of Artificial Organs, 1994Co-Authors: Teut Risler, Braun N, Hanel Kd, Ulrich Kuhlmann, Skroch D, G. A. MüllerAbstract:Hemodialysis is not an absolute prerequisite for the formation of beta 2-Microglobulin amyloidosis, but it enhances the progression of this complication related to long-standing renal failure. Thus the clearance and turnover of beta 2-Microglobulin seems to play a major role in this disease. In a prospective multicenter study the beta 2-Microglobulin clearance was studied in 87 patients starting hemodialysis. Serum samples were taken prior to and after the first dialysis session and also before and after dialysis at 4, 6, 12, 16, 26 and 52 weeks. Patients were either treated by cuprophane or a polyacrylonitril membrane. At the start, the mean serum beta 2-Microglobulin level was about 18 mg/L in patients treated with a cuprophane membrane, but the levels increased after hemodialysis and reached a plateau, which was always higher than in those treated with polyacrylonitril, which cleared beta 2-Microglobulin from the serum. However, after 12 months the difference was no longer significant. Thus beta 2-Microglobulin excretion during dialysis differs between the two membranes, but seems to lose its significance for the beta 2-Microglobulin serum level in chronic hemodialysis treatment.
Polcáková M - One of the best experts on this subject based on the ideXlab platform.
-
Beta 2-Microglobulin and tumors of the central nervous system
Ceskoslovenská neurologie a neurochirurgie, 1990Co-Authors: Hrazdirová, Hrazdira Cl, Polcáková MAbstract:In 60 patients with tumours of the central nervous system (50 intracranial, 10 intraspinal) the beta 2-Microglobulin in serum and cerebrospinal fluid was examined. The frequency of pathological finding was in both examined fluids considerable and differed with regard to the type and site of the tumours; it was particularly high in intracranial gliomas (in serum 87.1%, in cerebrospinal fluid 74.2%). For comparison a group of 55 patients with multiple sclerosis was examined where the incidence of elevated beta 2-Microglobulin was markedly lower (in serum 29.1%, in cerebrospinal fluid 20%). Normal values in serum and cerebrospinal fluid were obtained in 50 subjects without organic lesions of the nervous system.
Tom F. Parker - One of the best experts on this subject based on the ideXlab platform.
-
The effect of membrane biocompatibility on plasma beta 2-Microglobulin levels in chronic hemodialysis patients.
Journal of The American Society of Nephrology, 1996Co-Authors: Raymond M. Hakim, Rebecca L. Wingard, Leigh Husni, Robert A. Parker, Tom F. ParkerAbstract:Several studies have shown that patients who have been dialyzed with high-flux biocompatible membranes have a lower plasma level of beta 2-Microglobulin and a lower incidence of amyloid disease compared with patients who have been dialyzed with low-flux bioincompatible membranes. However, because high-flux membranes are associated with significant dialytic removal of beta 2-Microglobulin, the specific role of membrane biocompatibility in influencing the rate of increase of beta 2-Microglobulin has not been previously determined. This study investigated the effect of biocompatibility on the rate of increase of plasma levels of beta 2-Microglobulin in 159 new hemodialysis patients from 13 dialysis centers (ten centers affiliated with Dallas Nephrology Associates and three with Vanderbilt University Medical Center) by using two low-flux membranes with widely different biocompatibilities. These patients were prospectively randomized to be dialyzed with either a low-flux biocompatible membrane or a low-flux bioincompatible membrane. Plasma beta 2-Microglobulin levels were measured at 0, 3, 6, 9, 12, and 18 months. Sixty-six patients completed the 18-month study. Plasma beta 2-Microglobulin increased in all patients; however, the increase was not significantly different from baseline at any time point in the group that used the biocompatible membrane. In this group, beta 2-Microglobulin increased from (mean +/- SD) 27.8 +/- 14.8 mg/L to 34.0 +/- 10.0 mg/L at 18 months (P = not significant), and the mean increase at 18 months was 2.6 +/- 14.7 mg/L. In contrast, the increase in plasma beta 2-Microglobulin level in the bioincompatible membrane group became significant in Month 6 when the levels had increased from a baseline of 24.8 +/- 9.6 mg/L to 29.5 +/- 12.2 mg/L (P
